1407155-91-2Relevant academic research and scientific papers
Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
Aoki, Toshiaki,Yoshizawa, Hidenori,Yamawaki, Kenji,Yokoo, Katsuki,Sato, Jun,Hisakawa, Shinya,Hasegawa, Yasushi,Kusano, Hiroki,Sano, Masayuki,Sugimoto, Hideki,Nishitani, Yasuhiro,Sato, Takafumi,Tsuji, Masakatsu,Nakamura, Rio,Nishikawa, Toru,Yamano, Yoshinori
, p. 847 - 868 (2018/07/03)
The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae. Cefiderocol (3) was one of the best molecules which displayed well-balanced and potent activities against multi-drug resistant Gram-negative pathogens including carbapenem resistant bacteria among the prepared compounds with the modified C-7 side chain and the modified C-3 side chain. Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-negative infection.
NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE
-
Paragraph 0233, (2014/03/25)
The present invention provides a novel compound which has a wide antimicrobial spectrum, and in particular exhibits potent antimicrobial activity against beta-lactamase producing Gram negative bacteria. Specifically, the present invention provides a compound of the formula (I): wherein each symbol is as defined in the specification, or an amino-protected compound when the amino group is present on the ring in the 7-side chain, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.
